These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 2380653

  • 1. Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man.
    O'Halloran DJ, Nikou GC, Kreymann B, Ghatei MA, Bloom SR.
    J Endocrinol; 1990 Jul; 126(1):169-73. PubMed ID: 2380653
    [Abstract] [Full Text] [Related]

  • 2. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.
    Schjoldager BT, Mortensen PE, Christiansen J, Orskov C, Holst JJ.
    Dig Dis Sci; 1989 May; 34(5):703-8. PubMed ID: 2714145
    [Abstract] [Full Text] [Related]

  • 3. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man.
    Wettergren A, Maina P, Boesby S, Holst JJ.
    Scand J Gastroenterol; 1997 Jun; 32(6):552-5. PubMed ID: 9200286
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.
    Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ.
    Scand J Gastroenterol; 1994 Jun; 29(6):501-5. PubMed ID: 7915853
    [Abstract] [Full Text] [Related]

  • 5. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    Digestion; 1992 Jun; 52(3-4):214-21. PubMed ID: 1459356
    [Abstract] [Full Text] [Related]

  • 6. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.
    Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ.
    Gut; 1997 May; 40(5):597-601. PubMed ID: 9203936
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of human gastric lipase secretion by glucagon-like peptide-1.
    Wøjdemann M, Wettergren A, Sternby B, Holst JJ, Larsen S, Rehfeld JF, Olsen O.
    Dig Dis Sci; 1998 Apr; 43(4):799-805. PubMed ID: 9558037
    [Abstract] [Full Text] [Related]

  • 8. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.
    Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ.
    Dig Dis Sci; 1993 Apr; 38(4):665-73. PubMed ID: 8462365
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
    Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ.
    Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of the C-terminal octapeptide of oxyntomodulin on pentagastrin-stimulated gastric acid secretion in man.
    Veyrac M, Ribard D, Daures JP, Mion H, Lequellec A, Martinez J, Bataille D, Michel H.
    Scand J Gastroenterol; 1989 Dec; 24(10):1238-42. PubMed ID: 2690315
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.
    Wøjdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2513-7. PubMed ID: 10404829
    [Abstract] [Full Text] [Related]

  • 12. Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2.
    Schepp W, Schmidtler J, Riedel T, Dehne K, Schusdziarra V, Holst JJ, Eng J, Raufman JP, Classen M.
    Eur J Pharmacol; 1994 Oct 14; 269(2):183-91. PubMed ID: 7851494
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.
    Am J Physiol; 1997 Nov 14; 273(5):E981-8. PubMed ID: 9374685
    [Abstract] [Full Text] [Related]

  • 14. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M.
    J Clin Invest; 1998 Apr 01; 101(7):1421-30. PubMed ID: 9525985
    [Abstract] [Full Text] [Related]

  • 15. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs.
    Fung LC, Chisholm C, Greenberg GR.
    Endocrinology; 1998 Jan 01; 139(1):189-94. PubMed ID: 9421414
    [Abstract] [Full Text] [Related]

  • 16. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
    Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA.
    J Clin Endocrinol Metab; 2003 Apr 01; 88(4):1772-9. PubMed ID: 12679472
    [Abstract] [Full Text] [Related]

  • 17. Oxyntomodulin (glucagon-37) and its C-terminal octapeptide inhibit gastric acid secretion.
    Jarrousse C, Audousset-Puech MP, Dubrasquet M, Niel H, Martinez J, Bataille D.
    FEBS Lett; 1985 Aug 19; 188(1):81-4. PubMed ID: 4018272
    [Abstract] [Full Text] [Related]

  • 18. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans.
    Layer P, Holst JJ, Grandt D, Goebell H.
    Dig Dis Sci; 1995 May 19; 40(5):1074-82. PubMed ID: 7729267
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.